BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 9255199)

  • 21. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
    Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
    Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-transplantation lymphoproliferative disease in pediatric liver recipients in Taiwan.
    Hsu CT; Chang MH; Ho MC; Chang HH; Lu MY; Jou ST; Ni YH; Chen HL; Hsu HY; Wu JF
    J Formos Med Assoc; 2019 Nov; 118(11):1537-1545. PubMed ID: 30630698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
    McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
    Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C.
    McLaughlin K; Wajstaub S; Marotta P; Adams P; Grant DR; Wall WJ; Jevnikar AM; Rizkalla KS
    Liver Transpl; 2000 Sep; 6(5):570-4. PubMed ID: 10980055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adult post-transplant lymphoproliferative disease in the liver graft in patients with recurrent hepatitis C.
    Kim RD; Fujikawa T; Mizuno S; Schwartz JJ; Sorensen JB; Hemming AW; Fujita S
    Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):559-65. PubMed ID: 21555941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level.
    Eshraghian A; Imanieh MH; Dehghani SM; Nikeghbalian S; Shamsaeefar A; Barshans F; Kazemi K; Geramizadeh B; Malek-Hosseini SA
    World J Gastroenterol; 2017 Feb; 23(7):1224-1232. PubMed ID: 28275302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
    Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus.
    Hierro L; Díez-Dorado R; Díaz C; De la Vega A; Frauca E; Camarena C; Muñoz-Bartolo G; González de Zárate A; López Santamaría M; Jara P
    Liver Transpl; 2008 Aug; 14(8):1185-93. PubMed ID: 18668670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One hundred children treated with tacrolimus after primary orthotopic liver transplantation.
    McDiarmid S; Goss J; Seu P; Shackleton C; Vargas J; Ament M; Busuttil R
    Transplant Proc; 1998 Jun; 30(4):1397-8. PubMed ID: 9636564
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation.
    Jain A; Mazariegos G; Kashyap R; Green M; Gronsky C; Starzl TE; Fung J; Reyes J
    Transplantation; 2000 Aug; 70(4):617-25. PubMed ID: 10972220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience.
    Pinho-Apezzato ML; Tannuri U; Tannuri AC; Mello ES; Lima F; Gibelli NE; Santos MM; Ayoub AA; Maksoud-Filho JG; Velhote MC; Silva MM; Andrade WC; Miyatani HT
    Transplant Proc; 2010 Jun; 42(5):1763-8. PubMed ID: 20620519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term survival after post-transplant lymphoproliferative disease in children.
    Nathanson S; Debray D; Delarue A; Deschênes G
    Pediatr Nephrol; 2002 Aug; 17(8):668-72. PubMed ID: 12185479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder.
    Preiksaitis JK; Diaz-Mitoma F; Mirzayans F; Roberts S; Tyrrell DL
    J Infect Dis; 1992 Nov; 166(5):986-94. PubMed ID: 1328412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus.
    Fridell JA; Jain A; Reyes J; Biederman R; Green M; Sindhi R; Mazariegos GV
    Transplantation; 2002 Dec; 74(12):1721-4. PubMed ID: 12499888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
    Quintini C; Kato T; Gaynor JJ; Ueno T; Selvaggi G; Gordon P; McLaughlin G; Tompson J; Ruiz P; Tzakis A
    Transplant Proc; 2006; 38(6):1755-8. PubMed ID: 16908272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation.
    Cox KL; Lawrence-Miyasaki LS; Garcia-Kennedy R; Lennette ET; Martinez OM; Krams SM; Berquist WE; So SK; Esquivel CO
    Transplantation; 1995 Feb; 59(4):524-9. PubMed ID: 7533344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease.
    Mañez R; Breinig MC; Linden P; Wilson J; Torre-Cisneros J; Kusne S; Dummer S; Ho M
    J Infect Dis; 1997 Dec; 176(6):1462-7. PubMed ID: 9395355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
    Mendizabal M; Marciano S; dos Santos Schraiber L; Zapata R; Quiros R; Zanotelli ML; Rivas MM; Kusminsky G; Humeres R; Alves de Mattos A; Gadano A; Silva MO
    Clin Transplant; 2013; 27(4):E469-77. PubMed ID: 23758407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.